Cohort studies have identified the overexpression of ERG and ETS2 as a biomarker correlated with an adverse clinical outcome in AML patients, with ETS2 hypothesized to induce apoptosis (in the presence of p53) and ERG crucial for leukemic maintenance (96–100). Here, ERG is linked to acute myeloid leukemia.